<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aberrant janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling is involved in the <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> of several <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Suppressors of cytokine signaling (SOCS) genes and SH2-containing protein tyrosine phosphatase 1 (SHP1) proteins, which are negative regulators of JAK/STAT signaling, have been reported to have <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor functions </plain></SENT>
<SENT sid="2" pm="."><plain>However, in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cells, the mechanisms that regulate SOCS and SHP1 genes, and the cause of abnormalities in the JAK/STAT signaling pathway, remain largely unknown </plain></SENT>
<SENT sid="3" pm="."><plain>The present study shows that <z:chebi fb="0" ids="46024">trichostatin A</z:chebi> (TSA), a <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase (HDAC) inhibitor, leads to the hyperacetylation of <z:chebi fb="0" ids="15358">histones</z:chebi> associated with the SOCS1 and SOCS3 promoters, but not the SHP1 promoter in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>This indicates that <z:chebi fb="0" ids="15358">histone</z:chebi> modifications are involved in the regulation of SOCS1 and SOCS3 </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, upregulation of SOCS1 and SOCS3 expression was achieved using TSA, which also significantly downregulated JAK2/STAT3 signaling in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="6" pm="."><plain>We also demonstrate that TSA suppresses the growth of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells, and induces G1 cell cycle arrest and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> through the regulation of downstream targets of JAK2/STAT3 signaling, including Bcl-2, survivin and p16(ink4a)  </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, our data demonstrate that TSA may induce SOCS1 and SOCS3 expression by inducing <z:chebi fb="0" ids="15358">histone</z:chebi> modifications and consequently inhibits JAK2/STAT3 signaling in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="8" pm="."><plain>These results also establish a mechanistic link between the inhibition of JAK2/STAT3 signaling and the anticancer action of TSA in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
</text></document>